StockNews.AI
ALT
StockNews.AI
67 days

Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions

1. Altimmune to present pemvidutide at ADA's 85th Scientific Sessions. 2. Pemvidutide targets MASH, obesity, AUD, and ALD treatments. 3. FDA granted Fast Track designation for pemvidutide's MASH treatment. 4. Top-line results from IMPACT Phase 2b trial expected in Q2 2025. 5. Presentations include data on cardiovascular safety and fat reduction.

6m saved
Insight
Article

FAQ

Why Bullish?

The upcoming presentations and FDA designation highlight pemvidutide's strong potential, similar to prior biotech successes like Wegovy.

How important is it?

Strong presentation and interim data can influence investor sentiment and trading patterns significantly.

Why Short Term?

Immediate interest from the upcoming ADA conference can drive short-term stock activity.

Related Companies

NVDAAMGN
June 13, 2025 07:30 ET  | Source: Altimmune, Inc GAITHERSBURG, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association’s (ADA) 85th Scientific Sessions, to be held in Chicago, IL from June 20-23, 2025. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). Details for the oral presentation are as follows: Session Title:Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials Testing Incretin-Based Therapies – Take 1Session Date/Time:Saturday, June 21, 2025, 4:30 PM - 6:00 PM CDTPresentation Title:Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or OverweightPresenter:John J. Suschak, Ph.D., Senior Director, Translational Science, AltimmunePresentation Date/Time:Saturday, June 21, 2025 at 5:45 PM CDT Details of the poster presentations are as follows: Title:Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment (poster #749-P)Presenter:Shaheen Tomah, M.D., Director, Clinical Development, AltimmunePresentation Date/Time:Sunday, June 22, 2025, 12:30 PM - 1:30 PM CDT Title:Non-invasive Tests of Central Adiposity Correlate with Reductions in MRI-measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide (poster #748-P)Presenter:Shaheen Tomah, M.D., Director, Clinical Development, AltimmunePresentation Date/Time:Sunday, June 22, 2025, 12:30 PM - 1:30 PM CDT Title:Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Enhances Reverse Cholesterol Transport in a Golden Syrian Hamster Model (poster #778-P)Presenter:John J. Suschak, Ph.D., Senior Director, Translational Science, AltimmunePresentation Date/Time:Sunday, June 22, 2025, 12:30PM - 1:30 PM CDT These presentations will be accessible on the Events section of the Altimmune website. About PemvidutidePemvidutide is a novel, investigational, peptide-based 1:1 GLP-1/glucagon dual receptor agonist in development for the treatment of MASH, obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to date, once-weekly pemvidutide has demonstrated compelling weight loss with class-leading lean mass preservation, and robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide completed the MOMENTUM Phase 2 obesity trial in 2024 and is being studied in the ongoing IMPACT Phase 2b MASH trial with top line results expected in Q2 2025. IND applications in AUD and ALD have received FDA clearance with the Phase 2 trial in AUD having commenced in Q2 2025 and the ALD trial scheduled to commence in Q3 2025. About AltimmuneAltimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter Company Contact:Greg WeaverChief Financial OfficerPhone: 240-654-1450ir@altimmune.com Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com Media Contact:Jake RobisonInizio Evoke, BiotechPhone: 619-849-5383jake.robison@inizioevoke.com This press release was published by a CLEAR® Verified individual.

Related News